2025 Clinical Trials Treatment 
Miss Marijuana
FEBRUARY 7, 2025
As of 2025 , the legal status of THC and CBD is still evolving. When it comes to chronic pain treatment , CBD has shown promise in conditions like fibromyalgia , multiple sclerosis , and nerve pain. That said, it’s always best to consult a healthcare professional before switching from prescription medication to CBD-based treatments.
Miss Marijuana
FEBRUARY 1, 2025
Whether it’s easing pain or fighting nausea, cannabis is becoming a game-changer for cancer treatment. Well, cancer treatment can come with some seriously uncomfortable side effects, like pain, nausea, and loss of appetite. Ongoing research is diving deep into how cannabis can help people going through cancer treatment.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Puff Puff Post
DECEMBER 28, 2018
The Current Treatments for Autism. Most education-based autism treatment is focused on teaching developing children self-care, communicative, and social skills. Most education-based autism treatment is focused on teaching developing children self-care, communicative, and social skills. Instead, CBD is being used.
Cannabis Law Report
SEPTEMBER 13, 2021
(Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage pharmaceutical company committed to extending healthy lifespan, today announced that it intends to initiate dosing for a Phase 2 trial of MYMD-1’s function in delaying aging early in the fourth quarter of 2021. in the blood.
Cannabis Law Report
DECEMBER 23, 2021
billion by 2025. However, no single cannabinoid drug has received widespread approval in the treatment of pain. The market sizing section provides forecasts on the estimated sales of the three most lucrative cannabinoid pharmaceuticals – from 2021-2025 – including Epidiolex, Sativex and Dronabinol.
Cannabis Law Report
JUNE 25, 2021
billion in 2025 at a CAGR of 14%. EMA also regulates and supervises the drug quality, check for the intended use of the drug and whether the drug is meeting the requirement of clinical trial. MorphoSys and LEO Pharma strategically worked together to develop antibodies pertaining to the treatment of skin cancer.
Cannabis Law Report
NOVEMBER 16, 2021
Our treatment designed for delaying aging has a distinctive drug profile of oral delivery, selectivity, and very low toxicity as compared with TNF blockers, all of which are delivered by injection only. “For President, Director and Chief Medical Officer of MyMD. tumor necrosis factor receptor I (TNFRI) and IL-6.
Expert insights. Personalized for you.
Let's personalize your content